Beliefs, Attitudes, and Response to Genetic Testing in Sarcoma Patients
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
Genomic research has shown that a portion of leiomyosarcomas can be attributed to an underlying cancer predisposition syndrome. However, the optimal approach for incorporating germline testing into the care of these patients. This study is assessing the beliefs about the heritability of leiomyosarcoma and other cancer risks, and attitudes towards germline testing among leiomyosarcoma patients.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:
• Actionable germline PV detected in the research context
• Living
• No prior germline testing for this PV
• Able to speak and read English
• Mentally competent
• Age 18 or older
⁃ Relative of LMS Proband
• 25-50% chance for having inherited the PV
• No prior germline testing for this PV
• Able to speak and read English
• Mentally competent
• Age 18 or older
Locations
United States
Utah
Huntsman Cancer Institute at the University of Utah
RECRUITING
Salt Lake City
Contact Information
Primary
Gregg Wood
gregg.wood@hci.utah.edu
8016464215
Time Frame
Start Date: 2024-07-09
Estimated Completion Date: 2027-08
Participants
Target number of participants: 300
Treatments
LMS Probands
LMS Probands are the first person in a family to be known to have a germline predisposition gene mutation in LMS. A cohort of patients with a histologically confirmed leiomyosarcoma diagnosis will be prospectively recruited from two SPORE prospective biomarker studies.
Relative of LMS Probands
Relatives to LMS probands will be enrolled in this cohort. Approximately 4 family members per proband will be recruited.
Related Therapeutic Areas
Sponsors
Leads: University of Utah
Collaborators: University of Michigan, University of New South Wales, National Cancer Institute (NCI)